RxDoctor Payments Data

Alina Brener, MD

Cardiovascular Disease · Urbana, ILNPI 1154716330

Payments from drug & device makers

$10,571in general payments, 2019–2025

Across 27 payments — averaging $391.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$8K
  • Abbott$2K
  • Biosense Webster, Inc.$147
  • Cardiovascular Systems Inc.$129
  • Johnson & Johnson$120
  • Amgen$105
  • plus $344 from 6 others

What the payments were for

  • Consulting fees$7,68073%
  • Travel & lodging$1,41113%
  • Food & beverage$1,29512%
  • Education$811%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,571 in reported general payments places this provider in the 75th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$93,612
Medicare patients
1,377
Services billed
2,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten28$228,114
JardianceEmpagliflozin117$144,693
EliquisApixaban103$113,459
Repatha SureclickEvolocumab78$61,264
EntrestoSacubitril/Valsartan38$44,254
XareltoRivaroxaban15$15,949
Praluent PenAlirocumab20$12,489
Repatha PushtronexEvolocumab11$7,875
VascepaIcosapent Ethyl11$6,127
Repatha SyringeEvolocumab11$6,058
Metoprolol Succinate243$3,343
Icosapent Ethyl11$2,498
Atorvastatin Calcium203$2,416
Ezetimibe48$1,457
Amlodipine Besylate147$1,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$7,791$228,11428 claims
NovartisEntresto$33$44,25438 claims
Johnson & JohnsonXarelto$120$15,94915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Urbana

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →